great annual report

I like the way this Company conducts itself.

Outlook....

"The commercially significant progress of the past financial year has positioned Tissue Therapies well to capitalise on the opportunity to transform the lives of millions of people suffering from non-healing skin wounds, and to potentially provide shareholderrs with excellent reruns.

"Negotiations with a short-list of commercialisation partners for wound care products are progressing well and over the coming months the Board anticipates that these negotiations will be complete.

"While the advanced wound care market is the key short-to-medium term strategic focus of the Company, Tissue Therapies is proceeding with developing other commercial applications for VitroGrow, and other technologies, for the treatment of psoriasis, scar prevention, and treatment and potential treatments for various cancers including breast, colon and prostate.

"We look forward to providing further updates on these activities and particularly on future revenue streams from commercial products using VitroGrow and other technologies."

All of which begs the question, how much is Tissue Therapies REALLY worth? No wonder there's increasing market interest.

While VitroGrow is clearly a platform technology with application across a broad range of medical conditions, illness and disease, the Company also appears to be well advanced in the wider regenerative medicine space.

Conclusion: Tissue Therapies is rapidly developing into one of the more compelling stories in Australian, (if not global), biotech.

IMO :)